Piper Jaffray Starts Voyager Therapeutics (VYGR) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Chardan Capital Markets Starts Voyager Therapeutics (VYGR) at Sell
December 9, 2015 9:55 AM ESTChardan Capital Markets initiated coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Sell rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Voyager Therapeutics click here. For more ratings news on Voyager Therapeutics click here.
Shares of Voyager Therapeutics closed at $30.11 yesterday.
... MoreWedbush Starts Voyager Therapeutics (VYGR) at Outperform
December 7, 2015 7:42 AM ESTWedbush initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Outperform rating and a price target of $36.00.
Analyst David Nierengarten highlighted:
Pioneering AAV-based gene therapy for serious diseases of the central nervous system (CNS). VYGR has selected a number of CNS diseases with validated, specific gene targets that are amenable to AAV gene therapy. The CNS represents an ideal site for gene therapy due to its immune privilege status and terminally-differentiated cells that allow long-term transgene... MoreCowen Starts Voyager Therapeutics (VYGR) at Outperform
December 7, 2015 6:30 AM ESTCowen initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Outperform rating.
Analyst Phil Nadeau commented, "Voyagers lead program is VY-AADC01 for the treatment of advanced Parkinsons disease which is on track to produce proof-of-concept data in 2016. We estimate that VY-AADC01... More
